COVID-19 vaccination during pregnancy: coverage and safety

• DOI: 10.1016/j.ajog.2021.08.007
• Publication Date: 2021-08-10T06:49:41Z
• Authors: Helena Blakeway; Smriti Prasad; Erkan Kalafat; Paul T. Heath; Shamez N. Ladhani; Kirsty Le Doare; Laura A. Magee; Pat O’Brien; Arezou Rezvani; Peter von Dadelszen; Asma Khalil
• Keywords: Adult; Coverage; COVID-19 Vaccines; Fever; mRNA; coverage; 610; Black People; immunization; Congenital Abnormalities; 03 medical and health sciences; Viral vector; 0302 clinical medicine; Asian People; Pregnancy; ChAdOx1 nCoV-19; Intensive Care Units, Neonatal; Ethnicity; Humans; BNT162 Vaccine; Original Research; Coverage; COVID-19; Immunization; mRNA; Pregnancy; Safety vaccine uptake; SARS-CoV-2; Vaccination; Viral vector; SARS-CoV-2; Cesarean Section; Vaccination; viral vector; Age Factors; COVID-19; vaccination; 3. Good health; Intensive Care Units; Caribbean Region; Case-Control Studies; Obstetrics and gynecology; Infant, Small for Gestational Age; Immunization; Female; pregnancy; safety vaccine uptake; Safety vaccine uptake; 2019-nCoV Vaccine mRNA-1273

(Am J Obstet Gynecol. 2022;226:236.e1–14) While the pregnant population was not included in initial randomized controlled safety and efficacy trials of the COVID-19 vaccines, some limited data on the vaccine during pregnancy came from the CDC V-safe health checker, some inadvertent pregnancies in vaccine trials, and a formal pregnancy registry. While the COVID-19 vaccines do not contain a live virus and are theoretically considered safe in pregnancy, not all health care professionals have recommended routine vaccination since the start of vaccine rollout. This study examines the safety of COVID-19 in pregnant women, the rate of uptake, and outcomes of vaccinated pregnant individuals compared with the unvaccinated pregnant population.